Diagnostic yield of screening for SARS-CoV-2 among patients admitted to hospital for alternate diagnoses: an observational cohort study
ObjectivesTo determine the diagnostic yield of screening patients for SARS-CoV-2 who were admitted with a diagnosis unrelated to COVID-19 and to identify risk factors for positive tests.DesignCohort from the Canadian COVID-19 Emergency Department Rapid Response Network registry.Setting30 acute care...
Saved in:
Published in | BMJ open Vol. 12; no. 8; p. e057852 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
British Medical Journal Publishing Group
01.08.2022
BMJ Publishing Group LTD BMJ Publishing Group |
Series | Original research |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | ObjectivesTo determine the diagnostic yield of screening patients for SARS-CoV-2 who were admitted with a diagnosis unrelated to COVID-19 and to identify risk factors for positive tests.DesignCohort from the Canadian COVID-19 Emergency Department Rapid Response Network registry.Setting30 acute care hospitals across Canada.ParticipantsPatients hospitalised for non-COVID-19-related diagnoses who were tested for SARS-CoV-2 between 1 March and 29 December 2020.Main outcomePositive nucleic acid amplification test for SARS-CoV-2.Outcome measureDiagnostic yield.ResultsWe enrolled 15 690 consecutive eligible adults who were admitted to hospital without clinically suspected COVID-19. Among these patients, 122 tested positive for COVID-19, resulting in a diagnostic yield of 0.8% (95% CI 0.64% to 0.92%). Factors associated with a positive test included presence of fever, being a healthcare worker, having a positive household contact or institutional exposure, and living in an area with higher 7-day average incident COVID-19 cases.ConclusionsUniversal screening of hospitalised patients for COVID-19 across two pandemic waves had a low diagnostic yield and should be informed by individual-level risk assessment in addition to regional COVID-19 prevalence.Trial registration numberNCT04702945. |
---|---|
Bibliography: | Original research ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ISSN: | 2044-6055 2044-6055 |
DOI: | 10.1136/bmjopen-2021-057852 |